HIV With HBV/HCV Co-infection Tied to Higher Chance of Cancer

In HIV patients on anti-retroviral therapy (ART), chronic hepatitis B or C co-infection is linked to a higher incidence of non-Hodgkin’s lymphoma (NHL).

Highlights

Global prevalence of HIV infection is rising since persons on anti-retroviral treatment are living longer.
Incidence of non-Hodgkin’s lymphoma in persons with HIV infection is nearly ten times higher compared to normal population.
Certain infections such as hepatitis B (HBV) and hepatitis C (HCV) infections are also associated with an increased risk of non-Hodgkin’s lymphoma in immunocompromised persons.
Risk of non-Hodgkin’s lymphoma shown to be higher in HIV persons co-infected with HBV or HCV compared to non-infected persons.

HIV infected persons on anti-retroviral therapy, who have co-infection with hepatitis B or C have a higher risk of developing non-Hodgkin’s lymphoma, indicates a recent study.

Findings of the Study

The investigators analyzed 18 out of 33 cohorts from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) to determine if chronic HBV and HCV co- infection are associated with a higher occurrence of non-Hodgkin's lymphoma. The study initially included 52,479 ART-naïve patients, 40,219 of whom later began ART.

HIV Patients Still Face the Major Problem of Hepatitis C Despite Antiretroviral Therapy
The risk of hepatitis C associated serious liver disease still remains a problem in HIV patients who otherwise benefit from antiretrovial therapy to treat HIV, reveal a new study.

‘It is critical that early diagnosis of HIV is also combined with routine screening for chronic hepatitis B and C infections, to further reduce the risk of non-Hodgkin’s lymphoma (NHL).’

Some patients had associated HBV or HCV co-infection, while others had dual infection at the time of inclusion into cohorts. A few others acquired infection during the follow up phase. The authors found that the ART-treated patients having chronic HBV or HCV infection was at more risk of developing non-Hodgkin's lymphoma compared with those who were not infected.

Proposed Mechanisms of NHL in HIV infections

With anti-retroviral therapy (ART), survival of HIV infected persons has considerably improved. Additionally, with restoration of immunity following ART, the incidence of opportunistic infections and Kaposi sarcoma has also come down. Unfortunately, the expected decrease in AIDS related lymphomas has not decreased, and currently, HIV associated cancers, including NHL’s are becoming the leading causes of death in AIDS patients.

Currently, it is hypothesized that majority of AIDS-associated lymphomas (NHL) are caused by human γ-herpes viruses, mainly Kaposi sarcoma-herpes virus (KSHV) and to a lesser extent by Epstein-Barr virus (EBV) infections. The growth of these cancers is attributed to loss of immunoregulation due to immunosuppression induced by HIV infection.

Anti-retroviral Therapy for HIV Patients will also Treat HCV Infections
Researchers have found that using anti-retroviral therapy in treating HIV patients who are also infected with hepatitis C virus (HCV) will not only help deal with HIV, but also reduce HCV replication.

A lot of recent studies have evaluated the role of anti-herpes treatment in the prevention and treatment of AIDS-related lymphomas. Other modalities of treatment emerging include therapies targeting viral latency to kill infected tumor cells.

Proposed Mechanisms of NHL in HBV and HCV infections

Hepatitis B and C are hepatotropic (tendency to infect liver) viruses, and are associated with an increased risk of development of NHL, compared to the general population.

Research Predictors of Loss of Hepatitis B Surface Antigen in Patients Co-infected with HIV and HBV
It is well-documented that co-infection with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) poses a treatment challenge.

Three mechanisms have been suggested for hepatitis virus induced non-Hodgkin’s lymphoma.

These include:

Chronic antigenic stimulation of B cells by the viruses, followed by uncontrolled B-cell proliferation.
Interaction between the HCV-E2 receptor and CD 81 on B cells leading to polyclonal activation of naïve B cells.
Direct infection of B cells by the virus.

Whether these mechanisms act singly or in cohesion is not known, but researchers have suggested the importance of evaluating the efficacy of HBV and HCV vaccination in reducing the risk of NHL and other blood-related malignancies.

Synthetic Protein Molecule can Induce Self-destruction of Epstein Barr Infected Cancer Cells
American researchers have developed a synthetic protein molecule, which can induce self-destruction of cancer cells infected with the Epstein-Barr virus.

Lessons from the Study

It is probable that the mechanisms elaborated in the above paragraphs may exist and act in synergy in HIV patients co-infected with HBV and/or HCV, contributing to a much higher risk of development of NHL in this population.

The researchers conclude that early diagnosis and treatment of HIV infection should be combined with routine screening for chronic HBV an HCV infection. This is critical to further decrease non-Hodgkin's lymphoma associated morbidity and death in HIV-infected persons.

References:

Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities - (http://www.bloodjournal.org/content/117/6/1792?sso-checked=true)
Newly Emerging Therapies Targeting Viral-related Lymphomas - (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4041592/)
The Need for Investigations of Prophylactic Regimens to Prevent AIDS-Associated Non-Hodgkin's Lymphoma - (http://cid.oxfordjournals.org/content/30/5/762.full)

Source-Medindia